A novel selective progesterone receptor modulator asoprisnil activates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated signaling pathway in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 2, 2007, Pages 616-623

  Sasaki, Hiroko ^a   Ohara, Noriyuki ^a   Xu, Qin ^a   Wang, Jiayin ^a   DeManno, Deborah A ^b   Chwalisz, Kristof ^b   Yoshida, Shigeki ^a   Maruo, Takeshi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TAP PHARMACEUTICAL PRODUCTS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DERIVATIVE; ANTIGESTAGEN; ASOPRISNIL; CASPASE 3; CASPASE 7; CASPASE 8; DEATH RECEPTOR 4; DEATH RECEPTOR 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHENOLSULFONPHTHALEIN; PROGESTERONE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CULTURE MEDIUM; DOWN REGULATION; DRUG EFFECT; ENZYME DEGRADATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MYOMETRIUM; PRIORITY JOURNAL; SERUM; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; UPREGULATION; UTERUS MYOMA; WESTERN BLOTTING; X CHROMOSOME LINKAGE;

BOVINAE;

EID: 33846995100     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-0898     Document Type: Article

References (49)

1. Matsuo H, Maruo, T, Samoto T 1997 Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone. J Clin Endocrinol Metab 82:293-299
2. Shimomura Y, Matsuo H, Samoto T, Maruo T 1998 Up-regulation by progesterone of proliferating cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma. J Clin Endocrinol Metab 83:2192-2198
3. Maruo T, Ohara N, Wang J, Matsuo H 2004 Sex steroidal regulation of uterine leiomyoma growth and apoptosis. Hum Reprod Update 10:207-220
4. Leonhardt SA, Edwards DP 2002 Mechanism of action of progesterone antagonists. Exp Biol Med 227:969-980
5. Chwalisz K, Perez MC, DeManno D, Winkel C, Schubert G, Elger W 2005 Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev [Erratum (2005) 26:703] 26:423-438
6. DeManno D, Elger W, Garg R, Lee R, Schneider B, Hess-Stumpp H, Schubert G, Chwalisz K 2003 Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy. Steroids 68:1019-1032
7. Schubert G, Elger W, Kaufmann G, Schneider B, Reddersen G, Chwalisz K 2005 Discovery, chemistry, and reproductive pharmacology of asoprisnil and related 11β-benzaldoxime substituted selective progesterone receptor modulators (SPRMs). Semin Reprod Med 23:58-73
8. Chwalisz K, Parker RL, Williamson S, Larsen L, MaCrary K, Elger W 2003 Treatment of uterine leiomyomas with the novel selective progesterone receptor modulator (SPRM) J867. J Soc Gynecol Investig 10 (Suppl):301A
9. Chwalisz K, Larsen L, McCrary K, Edmonds A 2004 Effects of the novel selective progesterone receptor modulator (SPRM) asoprisnil on bleeding patterns in subjects with leiomyomata. J Soc Gynecol Investig 11(Suppl):320A-321A
10. Chen W, Ohara N, Wang JY, Xu Q, Liu J, Morikawa A, Sasaki H, Yoshida S, DeManno DA, Chwalisz K, Maruo T 2006 A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab 91:1296-1304
11. Wang J, Ohara N, Wang Z, Chen W, Morikawa A, Sasaki H, DeManno DA, Chwalisz K, Maruo T 2006 A novel selective progesterone receptor modulator (J867) down-regulates the expression of EGF, IGF-I, TGFβ3, and their receptors in cultured uterine leiomyoma cells. Hum Reprod 21:1869-1877
12. Wang S, El-Deiry WS 2003 TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22:8628-8633
13. Sheikh MS, Huang Y 2004 Death receptors as targets of cancer therapeutics. Curr Cancer Drug Targets 4:97-104
14. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH 1999 Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104:155-162
15. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ 2002 Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 168:1356-1361
16. Yagita H, Takeda K, Hayakawa Y, Smyth MJ, Okumura K 2004 TRAIL and its receptors as targets for cancer therapy. Cancer Sci 95:777-783
17. Hoffman PJ, Milliken DB, Gregg LC, Davis RR, Gregg JP 2004 Molecular characterization of uterine fibroids and its implication for underlying mechanisms of pathogenesis. Fertil Steril 83:639-649
18. Noyes RW, Hertig AT, Rock J 1950 Dating the endometrial biopsy. Fertil Steril 1:3-25
19. Siervo-Sassi RR, Marrangoni AM, Feng X, Naoumova N, Winans M, Edwards RP, Lokshin A 2003 Physiological and molecular effects of Apo2L/ TRAIL and cisplatin in ovarian carcinoma cell lines. Cancer Lett 190:61-72
20. Pieper AA, Verma A, Zhang J, Snyder SH 1999 Poly(ADP-ribose) polymerase, nitric oxide and cell death. Trends Pharmacol Sci 20:171-181
21. Eiletz J, Genz T, Pollow K, Schmidt-Gollwitzer M 1980 Sex steroid levels in serum, myometrium, and fibromyomata in correlation with cytoplasmic receptors and 17β-HSD activity in different age-groups and phases of the menstrual cycle. Arch Gynecol 229:13-28
22. Singh TR, Shankar S, Chen X, Asim M, Srivastava RK 2003 Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res 63:5390-5400
23. Wu GS, Burns TF, McDonald 3rd ER, Jiang W, Meng R, Krantz ID, Kao G, Gan DD, Zhou JY, Muschel R, Hamilton SR, Spinner NB, Markowitz S, Wu G, El-Deiry WS 1997 KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 17:141-143
24. Takimoto R, El-Deiry WS 2000 Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 19:1735-1743
25. Liu X, Yue P, Khuri FR, Sun S-Y 2004 p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res 64:5078-5083
26. Gao Z, Matsuo H, Nakago S, Kurachi O, Maruo T 2002 p53 tumor suppressor protein content in human uterine leiomyomas and its down-regulation by 17β-estradiol. J Clin Endocrinol Metab 87:3915-3920
27. Shetty S, Gladden JB, Henson ES, Hu X, Villanueva J, Haney N, Gibson SB 2002 Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFκB activation in epithelial derived cell lines. Apoptosis 7:413-420
28. Guan B, Yue P, Lotan R, Sun S-Y 2002 Evidence that the human death receptor 4 is regulated by activator protein 1. Oncogene 21:3121-3129
29. Drosopoulos KG, Roberts ML, Cermak L, Sasazuki T, Shirasawa S, Andera L, Pintzas A 2005 Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by up-regulating death receptor 4 and death receptor 5 through a MEK-dependent pathway. J Biol Chem 280:22856-22867
30. 2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1,9-dien-28-oate in human lung cancer cells. Cancer Res 64:7570-7578
31. Schimmer AD 2004 Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 64:7183-7190
32. Deveraux QL, Reed JC 1999 IAP family proteins-suppressors of apoptosis. Genes Dev 13:239-252
33. Zhang XD, Zhang XY, Gray CP, Nguyen T, Heresy P 2001 Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by Smac/DIABLO release from mitochondria. Cancer Res 61:7339-7348
34. Amantana A, London CA, Iversen P, Devi GR 2004 X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Mol Cancer Ther 3:699-707
35. Kim EH, Kim SU, Shin DY, Choi KS 2004 Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP. Oncogene 23:446-456
36. Shi R-X, Ong C-N, Shen H-M 2005 Protein kinase C inhibition and X-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells. Cancer Res 65:7815-7823
37. Chai J, Du C, Wu J-W, Kyin S, Wang X, Shi Y 2000 Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature 406:855-862
38. XL inhibit CD95-mediated apoptosis by preventing mitochondrial release of Smac/DIABLO and subsequent inactivation of X-linked inhibitor-of-apoptosis protein. J Biol Chem 277:11345-11351
39. Shankar S, Srivastava RK 2004 Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist Updat 7:139-156
40. Thome M, Tschopp J 2001 Regulation of lymphocyte proliferation and death by FLIP. Nat Rev Immunol 1:50-58
41. Sharp DA, Lawrence DA, Ashkenazi A 2005 Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis. J Biol Chem 280:19401-19409
42. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P 1990 Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 9:1603-1614
43. Tung L, Mohamed MK, Hoeffler JP, Takimoto GS, Horwitz KB 1993 Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors. Mol Endocrinol 7:1256-1265
44. Vegeto E, Shahbaz MM, Wen DX, Goldman ME, O'Malley BW, McDonnell DP 1993 Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol Endocrinol 7:1244-1255
45. Wen DX, Xu Y-F, Mais DE, Goldman ME, McDonnell DP 1994 The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells. Mol Cell Biol 14:8356-8364
46. Xu Q, Ohara N, Chen W, Liu J, Sasaki H, Morikawa A, Sitruk-Ware R, Johansson EDB, Maruo T 2006 Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells. Hum Reprod 21:2408-2416
47. Smith CL, O'Malley BW 2004 Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25:45-71
48. Liu Z, Auboeuf D, Wong J, Chen JD, Tsai SY, Tsai M-J, O'Malley BW 2002 Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486. Proc Natl Acad Sci USA 99:7940-7944
49. Giangrande PH, Kimbrel EA, Edwards DP, McDonnell DP 2000 The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding. Mol Cell Biol 20:3102-3115